Ultragenyx Pharmaceutical Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
RARE$15.43-0.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
During the three months ended June 30, 2026 the following directors and Section 16 officers adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Name and Title | Date Adopted | Aggregate Number of Shares of Common Stock to be Sold (Subject to Certain Conditions) | Plan End Date |
|---|---|---|---|
| Howard Horn, Executive Vice President, Chief Financial Officer, Corporate Strategy | June 5, 2026 | Up to 9,394 shares | June 4, 2027 |
| Theodore HuizengaSenior Vice President and Chief Accounting Officer | June 4, 2026 | Up to 4,726 shares | January 31, 2027 |
| John Pinion, EVP, Chief Quality Officer and Translational Sciences | May 19, 2026 | Up to 19,936 shares | May 18, 2027 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.